Rossana Trotta

Rossana Trotta

Auto-generated profile, based on publicly available information

Rossana Trotta

Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 1997 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
TSTomasz Skorski
Tomasz Skorski
ABAlfonso Bellacosa
Alfonso Bellacosa
MNMargaret Nieborowska‐Skorska
Margaret Nieborowska‐Skorska
MMMiroslaw Majewski
Miroslaw Majewski
RMRobert Martinez
Robert Martinez
BCBruno Calabretta
Bruno Calabretta
The BCR/ABL oncogenic tyrosine kinase activates phosphatidylinositol 3‐kinase (PI‐3k) by a mechanism that requires binding of BCR/ABL to p85, the regulatory subunit of PI‐3k, and an intact BCR/ABL SH2 domain. SH2 domain BCR/ABL mutants deficient in PI‐3k activation failed to stimulate Akt kinase, a recently identified PI‐3k downstream effector with oncogenic potential, but did activate p21 RAS and p70 S6 kinase. The PI‐3k/Akt pathway is essential for BCR/ABL leukemogenesis as indicated by experiments demonstrating that wortmannin, a PI‐3k specific inhibitor at low concentrations, suppressed BCR/ABL‐dependent colony formation of murine marrow cells, and that a kinase‐deficient Akt mutant with dominant‐negative activity inhibited BCR/ABL‐dependent transformation of murine bone marrow cells in vitro and suppressed leukemia development in SCID mice. In complementation assays using mouse marrow progenitor cells, the ability of transformation‐defective SH2 domain BCR/ABL mutants to induce growth factor‐independent colony formation and leukemia in SCID mice was markedly enhanced by expression of constitutively active Akt. In retrovirally infected mouse marrow cells, the BCR/ABL mutant lacking the SH2 domain was unable to upregulate the expression of c‐Myc and Bcl‐2; in contrast, expression of a constitutively active Akt mutant induced Bcl‐2 and c‐Myc expression, and stimulated the transcription activation function of c‐Myc. Together, these data demonstrate the requirement for the BCR/ABL SH2 domain in PI‐3k activation and document the essential role of the PI‐3k/Akt pathway in BCR/ABL leukemogenesis.

1 November 2005 in Cancer Cell
Verified
Journal Article
Closed access
PNPaolo Neviani
Paolo Neviani
RSRamasamy Santhanam
Ramasamy Santhanam
RTRossana Trotta
Rossana Trotta
MNMario Notari
Mario Notari
BBBradley Wayne Blaser
Bradley Wayne Blaser
DPDanilo Perrotti
Danilo Perrotti

4 September 2007 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
PNPaolo Neviani
Paolo Neviani
RSRamasamy Santhanam
Ramasamy Santhanam
JOJoshua J. Oaks
Joshua J. Oaks
Anna EiringAnna Eiring
Anna Eiring
MNMario Notari
Mario Notari
DPDanilo Perrotti
Danilo Perrotti
Blast crisis chronic myelogenous leukemia (CML-BC) and Philadelphia chromosome–positive (Ph1-positive) acute lymphocytic leukemia (ALL) are 2 fatal BCR/ABL-driven leukemias against which Abl kinase inhibitors fail to induce a long-term response. We recently reported that functional loss of protein phosphatase 2A (PP2A) activity is important for CML blastic transformation. We assessed the therapeutic potential of the PP2A activator FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol hydrochloride), an immunomodulator in Phase III trials for patients with multiple sclerosis or undergoing organ transplantation, in CML-BC and Ph1 ALL patient cells and in in vitro and in vivo models of these BCR/ABL+ leukemias. Our data indicate that FTY720 induces apoptosis and impairs clonogenicity of imatinib/dasatinib-sensitive and -resistant p210/p190BCR/ABL myeloid and lymphoid cell lines and CML-BCCD34+ and Ph1 ALLCD34+/CD19+ progenitors but not of normal CD34+ and CD34+/CD19+ bone marrow cells. Furthermore, pharmacologic doses of FTY720 remarkably suppress in vivo p210/p190BCR/ABL-driven [including p210/p190BCR/ABL (T315I)] leukemogenesis without exerting any toxicity. Altogether, these results highlight the therapeutic relevance of rescuing PP2A tumor suppressor activity in Ph1 leukemias and strongly support the introduction of the PP2A activator FTY720 in the treatment of CML-BC and Ph1 ALL patients.

20 December 2001 in Nature Genetics
Verified
Journal Article
Closed access
DPDanilo Perrotti
Danilo Perrotti
VCVincenzo Cesi
Vincenzo Cesi
RTRossana Trotta
Rossana Trotta
CGClara Guerzoni
Clara Guerzoni
GSGiorgia Santilli
Giorgia Santilli
BCBruno Calabretta
Bruno Calabretta

13 August 2009 in Blood
Verified
Journal Article
Closed access
PDF file
SCStefan Costinean
Stefan Costinean
SSSukhinder K. Sandhu
Sukhinder K. Sandhu
IPIrene M. Pedersen
Irene M. Pedersen
ETEsmerina Tili
Esmerina Tili
RTRossana Trotta
Rossana Trotta
CCCarlo Maria Croce
Carlo Maria Croce
We showed that Eμ-MiR-155 transgenic mice develop acute lymphoblastic leukemia/high-grade lymphoma. Most of these leukemias start at approximately 9 months irrespective of the mouse strain. They are preceded by a polyclonal pre–B-cell proliferation, have variable clinical presentation, are transplantable, and develop oligo/monoclonal expansion. In this study, we show that in these transgenic mice the B-cell precursors have the highest MiR-155 transgene expression and are at the origin of the leukemias. We determine that Src homology 2 domain–containing inositol-5-phosphatase (SHIP) and CCAAT enhancer-binding protein β (C/EBPβ), 2 important regulators of the interleukin-6 signaling pathway, are direct targets of MiR-155 and become gradually more down-regulated in the leukemic than in the preleukemic mice. We hypothesize that miR-155, by down-modulating Ship and C/EBPβ, initiates a chain of events that leads to the accumulation of large pre-B cells and acute lymphoblastic leukemia/high-grade lymphoma.

1 May 2006 in Immunity
Verified
Journal Article
Closed access
JYJianhua Yu
Jianhua Yu
MWMin Wei
Min Wei
BBBrian Becknell
Brian Becknell
RTRossana Trotta
Rossana Trotta
SLShujun Liu
Shujun Liu
MCMichael A. Caligiuri
Michael A. Caligiuri